Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal) (TA1135)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 February 2026
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) (TA1132)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 February 2026
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) (TA1078)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2025